Merck Starts a New Alzheimer's Trial

| No Comments

Merck & Co Inc is moving to the forefront of Alzheimer's disease research by starting a mid-stage study of a drug from a new class of oral medicines that aim to shut down production of a protein associated with the disease. The Phase II trial, which will compare the drug with a placebo, is a global, multi-center study that includes a group of 200 to test safety. The study is expected to eventually enroll up to 1,700 patients in the main Phase III Trial.
This study looks like it's a great example of an experiment. It has a placebo group (control group) and a group with the drug. I think if this experiment goes well, it will have excellent reliability and validity and move to the third stage of the trial.

Leave a comment

About this Entry

This page contains a single entry by mchal033 published on December 3, 2012 7:47 PM.

Brands/Football Stadium Survey Analysis was the previous entry in this blog.

Paper Towels Best Method For Drying Hands is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.